Are 'blades' considered medical devices?

'Blades' are frequently considered medical devices or accessories to medical devices, requiring their own regulatory classification, conformity assessment, and Unique Device Identification (UDI) in line with regulations such as EU MDR Article 2, Definition of 'accessory for a medical device,' and FDA 21 CFR Part 801 (Labeling) and Part 830 (UDI System).

What cybersecurity considerations arise from this model?

Cybersecurity must address the entire system, including the interfaces between the 'razor' and 'blade' if either component contains software or network connectivity. NIST SP 800-53 and FDA Pre-market Submissions for Management of Cybersecurity in Medical Devices guidance highlight the need for secure design and validation of interconnected components to prevent unauthorized access or manipulation of the MedTech system.

All terms

CommercializationAI / ML in Devices Hospital Buyer & Reimbursement

Razor / Razor-Blade Model

Sell capital equipment at low margin; recurring consumables drive profit.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

A business model where capital hardware (the 'razor') is placed at low margin or via no-capital programs to drive recurring sales of consumables, instruments, or single-use components (the 'razor blade'). Surgical robotics, EP mapping, blood-glucose monitoring, and IVD instruments classically follow this model.

What the regulation says

The Razor/Razor-Blade Model, while a commercial strategy, has regulatory implications primarily concerning the compatibility and interoperability of the "razor" (device) and "blade" (consumable/accessory) components. Regulations like the EU MDR (Regulation (EU) 2017/745) Annex I, General Safety and Performance Requirements (GSPR) 12.1 and 12.2, emphasize that devices must be designed and manufactured in such a way as to ensure the compatibility with other devices or accessories. The FDA also addresses this through its guidance on accessory devices and combination products, ensuring that the safety and effectiveness of the system as a whole are maintained, as outlined in 21 CFR Part 820, Quality System Regulation, which requires manufacturers to control product design and its interfaces.

What this means in practice

Pull-through per installed system is the operating metric that matters. CapEx-strapped buyers favor reagent-rental and managed-service variants.

Examples

A surgical robot (razor) requires proprietary surgical instruments (blades) for each procedure, which are sterilized and single-use, necessitating continuous reordering.
An in-vitro diagnostic (IVD) analyzer (razor) performs tests using specific reagent cartridges (blades) that are designed for that particular instrument.
A continuous glucose monitor (razor) relies on disposable sensors (blades) that require periodic replacement and recalibration for accurate readings.

Common pitfalls

•Manufacturers might face scrutiny if the "blade" component is designed to be proprietary in a way that creates an undue barrier to competition or compromises patient safety with alternative "blades."
•Failure to adequately test and validate the "razor" and "blade" components together can lead to regulatory non-compliance and adverse events.
•Changing a "blade" component, even a seemingly minor one, without proper regulatory submission and impact analysis can be considered an unauthorized modification to the MedTech system.
•The supply chain for both "razor" and "blade" components must be robust and controlled, as stockouts could lead to patient care disruptions and regulatory issues.

Frequently asked questions

Post-market surveillance must encompass both the 'razor' and 'blade' components. Any adverse events or quality issues related to either part, or their interaction, must be tracked and reported per regulations like 21 CFR Part 803 (Medical Device Reporting) or EU MDR Article 87 (Reporting of serious incidents and field safety corrective actions).

Grouped by theme

Editor's picks

· Hand-selected related concepts

Market Segments

In Vitro Diagnostics(IVD)

Tests performed on biological samples outside the body.

Market Segments

Surgical Robotics

Robotic systems that assist surgeons in performing operations.

More in Commercialization

· Same category

Commercialization

AdvaMed Code of Ethics

Industry code governing interactions between U.S. medical-device companies and healthcare professionals.

Commercialization

Advisory Board

Convening of external experts to advise on strategy or product.

Commercialization

Anti-Kickback Statute(AKS)

U.S. criminal statute prohibiting remuneration to induce federal healthcare business.

Commercialization

Bottom-Up Market Sizing

Building market size from procedure volumes × price × penetration.

Primary references

3 sources

Link health: 3 verified· last checked 2026-06-20

HBR·1AHRMM·1AdvaMed·1

Inline markers like [1] jump to the matching reference above.

On this term

Category: Commercialization
Sources: 3
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Sell capital equipment at low margin; recurring consumables drive profit.

·Pull-through per installed system is the operating metric that matters.
·CapEx-strapped buyers favor reagent-rental and managed-service variants.
·Surgical robotics, EP mapping, blood-glucose monitoring, and IVD instruments classically follow this model.

Remember this

Watch out: Manufacturers might face scrutiny if the "blade" component is designed to be proprietary in a way that creates an undue barrier to competition or compromises patient safety with alternative "blades."

Related terms

You may also need

Auto-suggested from Commercialization and shared keywords.

All Commercialization terms